Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow VACCINEX, INC.

Get SEC filing alerts via email and in your feed for VACCINEX, INC.

VCNX

VACCINEX, INC.

About VACCINEX, INC.

Vaccinex, Inc. is a biotech company developing targeted biotherapeutics for neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product, pepinemab, is an antibody targeting SEMA4D, aiming to modulate immune and inflammatory responses, promote tissue repair, and slow disease progression. The company leverages proprietary platforms like SEMA4D antibody and ActivMAb to address unmet medical needs in Alzheimer’s, Huntington’s, and various cancers.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from VACCINEX, INC.

1
1
VACCINEX, INC. Vaccinex Reports $18.6 Million Net Loss for 2024, Revenue Increases to $601,000

Via official filing (AI summary) | about 1 year ago | 0 comments

2
1
VACCINEX, INC. Vaccinex Reports Q3 Financial Results, Net Loss Improves Despite Revenue Decline

Via official filing (AI summary) | over 1 year ago | 0 comments